Drug companies are interested in diseases that millions of people get, ... That's where the profits are.
We're starting to understand the interaction of sickle blood with blood vessels, ... That's being now applied to treatments that actually improve outcome.
It's hard to get funding or people interested in trials, ... But because this is a lifelong, chronic problem, it has a greater impact.
